Investment analysts at Evercore ISI initiated coverage on shares of Axovant Sciences Ltd. (NYSE:AXON) in a research report issued on Friday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $30.00 price target on the biotechnology company’s stock. Evercore ISI’s price objective would indicate a potential upside of 46.63% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. Jefferies Group LLC restated a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a research report on Friday, June 9th. BidaskClub upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Cowen and Company restated an “outperform” rating and set a $30.00 target price on shares of Axovant Sciences in a research report on Wednesday, June 21st. CIBC upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 14th. Finally, Oppenheimer Holdings, Inc. upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $27.85.

Axovant Sciences (AXON) traded up 0.19% during mid-day trading on Friday, reaching $21.12. 438,821 shares of the company’s stock traded hands. The stock has a 50 day moving average of $21.49 and a 200 day moving average of $20.34. Axovant Sciences has a 12-month low of $11.01 and a 12-month high of $26.49. The company’s market cap is $2.27 billion.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12. On average, equities research analysts predict that Axovant Sciences will post ($2.41) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Evercore ISI Begins Coverage on Axovant Sciences Ltd. (AXON)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/10/axovant-sciences-ltd-axon-stock-rating-reaffirmed-by-evercore-isi.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its stake in Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after purchasing an additional 355 shares in the last quarter. American International Group Inc. raised its stake in Axovant Sciences by 7.1% during the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 998 shares in the last quarter. Legal & General Group Plc raised its stake in Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 1,168 shares in the last quarter. Teachers Advisors LLC raised its stake in Axovant Sciences by 5.2% during the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 2,038 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 2,072 shares in the last quarter.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.